secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093888
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla Q2 net loss $21.1M; cash to Q3 2025; Fast Track for ozuriftamab vedotin
-------------------------------------------------------------------------------

- Net loss of $21.1M for Q2 2024 vs $35.8M in Q2 2023; R&D expenses fell to $16.2M from $31.0M.
- Cash and equivalents $61.7M as of June 30, 2024, expected to fund operations through Q3 2025.
- Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track by FDA for SCCHN; FDA meeting for registrational trial expected in 2H 2024.
- Mecbotamab vedotin (CAB-AXL-ADC) Phase 2 in NSCLC shows OS trend in mutated KRAS; responses across G12A, G12C, G12V.
- Evalstotug (CAB-CTLA-4) combined Phase 1/2 safety: low grade 3 irAEs (4/40); Phase 2 melanoma data on track for 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000095017024093888/0000950170-24-093888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000095017024093888/bcab-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer